Tolpropamine

Tolpropamine

SCHEMBL4193587

Cc1ccc(C(CCN(C)C)c2ccccc2)cc1.Cl

nearest known ligand 0.78

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Tolpropamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 known ✓ P35367 7/20 0.78
HTR2A known ✓ P28223 6/20 0.78
CHRM2 known ✓ P08172 5/20 0.54
SLC6A2 known ✓ P23975 5/20 0.54
SLC6A4 known ✓ P31645 5/20 0.54
SCN1A known ✓ P35498 3/20 0.54
SCN2A known ✓ Q99250 3/20 0.54
SCN3A known ✓ Q9NY46 3/20 0.54
CHRM1 known ✓ P11229 4/20 0.48
SLC6A3 known ✓ Q01959 4/20 0.48
KCNH2 known ✓ Q12809 4/20 0.48
HRH3 known ✓ Q9Y5N1 4/20 0.48
ADRA2B known ✓ P18089 3/20 0.48
DRD1 known ✓ P21728 2/20 0.48
HTR2C known ✓ P28335 2/20 0.48
CHRM5 known ✓ P08912 2/20 0.48
HRH2 known ✓ P25021 2/20 0.48
ADRA1A known ✓ P35348 1/20 0.48
HTR2B known ✓ P41595 1/20 0.48
CHRM4 known ✓ P08173 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tolpropamine SCHEMBL29300 0.98 HRH1 (0.81) HRH1HTR2ACHRM2SLC6A2SLC6A4
Tolpropamine SCHEMBL1651656 0.95 HRH1 (0.75) HRH1HTR2ACHRM2SLC6A2SLC6A4
Hydrochloric Acid SCHEMBL11383046 0.90 HRH1 (0.95) HRH1HTR2ACHRM2SLC6A2SLC6A4
SCHEMBL1802493 0.88 HRH1 (1.00) HRH1HTR2ACHRM2SLC6A2SLC6A4
SCHEMBL29723649 0.82 CNR1 (0.56) HRH1HTR2ACHRM2SLC6A2SLC6A4
SCHEMBL10778672 0.81 HTR2A (0.78) HRH1HTR2ACHRM2SLC6A2SLC6A4
SCHEMBL14198390 0.79 CHRM2 (0.83) HRH1HTR2ACHRM2SLC6A2SLC6A4
SCHEMBL11382183 0.79 HRH1 (0.72) HRH1HTR2ACHRM2SLC6A2SLC6A4
Hydrochloric Acid SCHEMBL11374749 0.79 HTR2A (0.96) HRH1HTR2ACHRM2SLC6A2SLC6A4
SCHEMBL29101424 0.78 HRH1 (0.78) HRH1HTR2ACHRM2SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1696855-A1 DERMAL DRUG DELIVERY SYSTEM Medpharm Limited (GB) 2006-09-06 EP claimed
US-20060130266-A1 Dermal drug delivery system MEDPHARM LIMITED (GB) 2006-06-22 US claimed
WO-2005058226-A1 DERMAL DRUG DELIVERY SYSTEM MEDPHARM LIMITED (GB) 2005-06-30 WO claimed
US-20150328109-A1 DERMAL COMPOSITIONS CONTAINING UNNATURAL HYGROSCOPIC AMINO ACIDS MEDPHARM LIMITED (GB) 2015-11-19 US disclosed
EP-2916811-A1 DERMAL COMPOSITIONS CONTAINING UNNATURAL HYGROSCOPIC AMINO ACIDS MedPharm Limited (GB) 2015-09-16 EP disclosed
US-20150037394-A1 DRUG DELIVERY FORMULATIONS KING'S COLLEGE LONDON 2015-02-05 US disclosed
CN-103930093-A Drug delivery formulations KING S COLLEGE LONDON 2014-07-16 CN disclosed
WO-2014072747-A1 DERMAL COMPOSITIONS CONTAINING UNNATURAL HYGROSCOPIC AMINO ACIDS MEDPHARM LIMITED (GB) 2014-05-15 WO disclosed
EP-2723318-A2 DRUG DELIVERY FORMULATIONS King's College London (GB) 2014-04-30 EP disclosed
US-8349297-B2 Topical formulations MEDPHARM LIMITED (GB) 2013-01-08 US disclosed
WO-2012175996-A2 DRUG DELIVERY FORMULATIONS KING'S COLLEGE LONDON (GB) 2012-12-27 WO disclosed
EP-1931310-B1 Monophasic film-forming composition for topical administration MEDPHARM LTD (GB) 2012-06-06 EP disclosed
US-20090191271-A1 Topical Formulations MED PHARM LIMITED (GB) 2009-07-30 US disclosed
US-20060130266-A1 Dermal drug delivery system MEDPHARM LIMITED (GB) 2006-06-22 US disclosed
EP-1438942-A1 An otorhinological drug delivery device Schering Oy (FI) 2004-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150328109-A1 DERMAL COMPOSITIONS CONTAINING UNNATURAL HYGROSCOPIC AMINO ACIDS AADAT, HACL2, SLC6A15 HRH1 25/4885HTR2A 30/4885CHRM2 3160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.